Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4

Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4

This is a prospective, randomized double blind placebo controlled parallel group trial to assess dapagliflozin on surrogate markers of kidney and cardiovascular health in patients with stage 3b-4 Chronic Kidney Disease (CKD).
Randomization:
1) Dapagliflo3)zin 10mg (total dosage per day)
1) Placebo Dapagliflozin daily
This study includes three clinic in person visits and weekly telephone visits for 12 weeks.

Recruit 30 patients with CKD stages 3b-4 and randomize them in double-blind fashion to either placebo or dapagliflozin 10mg daily for 12 weeks
Determine the effect of interventions on the primary outcome variable serum klotho measured by immunoprecipitation-immunoblot

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 11, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments